Progesterone helped postmenopausal women fall asleep faster, but not sleep longer

Sleep complaints are common around and after menopause, and micronised progesterone is already part of many hormone therapy prescriptions, so whether it helps sleep in its own right is a practical question for a large group of women. There is a plausible mechanism: preclinical work shows progesterone metabolites act as positive modulators of the GABA type A receptor, the same receptor system many sleep medicines target. Individual trials, however, have reported mixed results. This review pooled the randomised evidence to see what the hormone reliably does to sleep.

The authors searched MEDLINE, Embase, PsycInfo and the Cochrane Central Register of Controlled Trials up to 31 March 2020 for randomised controlled trials of micronised progesterone with sleep outcomes. Nine published trials with 388 participants qualified, and one additional unpublished trial was found. Eight of the trials enrolled postmenopausal women. Sleep was measured objectively by polysomnography in some trials and by self-report in others, with results pooled using a random effects model.

Compared with placebo, micronised progesterone improved various sleep parameters on polysomnography, including total sleep time and sleep onset latency, though the studies were inconsistent with one another. When four trials were formally pooled, the result favoured progesterone for sleep onset latency, the time taken to fall asleep. Total sleep time and sleep efficiency did not reach significance in the pooled analysis. Self-reported sleep improved in most trials, but concurrent oestradiol use and improvements in hot flushes limit what can be concluded in some studies.

The finding lines up with the preclinical mechanism, giving the sleep effect biological plausibility rather than leaving it as a statistical curiosity. Still, the evidence base is small, the trials disagreed, and much of it involves women also taking oestrogen, which could be improving sleep by relieving hot flushes instead. The authors call for larger trials of progesterone on its own, measured with polysomnography or validated questionnaires. Until then the effect is best treated as promising rather than proven.

For women weighing up menopausal hormone therapy, this is useful context: the progesterone component may carry a sleep benefit of its own, most clearly for falling asleep sooner. The evidence does not show it lengthens sleep or makes it more efficient overall. Because the trials mostly studied postmenopausal women, the findings say little about anyone else. As with any hormone therapy question, this is information for a discussion with a clinician rather than a decision to make alone.